<a href="https://laohu8.com/S/PMHS">Polomar Health</a> Services Inc. Enters Amended Agreement with ForHumanity for Exclusive Marketing of Inhalable Medications
Polomar Health Services Inc., a Nevada-based corporation, has announced the execution of an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc., and Island Group 40, LLC. Effective August 19, 2025, this agreement grants ForHumanity exclusive marketing rights for Polomar's inhalable sildenafil and inhalable eletriptan products until March 31, 2026. The exclusivity can be extended based on revenue milestones, with potential extensions through December 31, 2026. Polomar Specialty Pharmacy, a wholly owned subsidiary, will handle prescription fulfillment, while IG4 will provide account management services. The agreement is set for an initial term ending September 16, 2028, with possible renewals contingent on achieving specific revenue targets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polomar Health Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-025989), on August 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.